Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06656572

Immunogenomic Analyses of Pediatric Catatonia

Rady Children's Institute for Genomic Medicine seeks to understand the genomes and immune systems in 40 children and adolescents who are admitted to Rady Children's Hospital San Diego with a catatonia diagnosis. Cutting-edge genome and protein sequencing technology will be used to better understand how immunological and genetic assessments may improve the ability to identify the cause of catatonia and impact care. The investigator also hopes to identify new genetic and/or autoimmune causes of catatonia that may inform new treatment for future patients.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

0 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Catatonia is a complex condition that affects children's behavior, movement, and emotions. It can be caused by various underlying health issues, such as genetic disorders or problems with the immune system. Identifying these underlying causes is crucial for providing the best care and treatment to affected children. In this study, the investigators aim to compare the effectiveness of traditional medical tests with a more advanced approach that includes genetic testing and immune system screening in finding the underlying causes of catatonia in children. The investigators will compare two groups of children with catatonia. One group will be identified from hospital records and will have undergone standard medical tests to find the cause of their catatonia. The other group will be a new set of patients who will receive both standard medical tests and additional advanced testing, including genome sequencing (a technique that reads the entire genetic code) and screening for antibodies that attack the brain. The investigators will use a statistical method called propensity score matching to make sure that the two groups are as similar as possible in terms of age, sex, and other relevant factors. This will help the investigators to fairly compare the effectiveness of the two approaches in identifying the underlying causes of catatonia. The investigators expect that combining standard medical tests with genome sequencing and autoantibody screening will be more effective in finding the underlying causes of catatonia in children compared to using standard medical tests alone. This could lead to more accurate diagnoses and more targeted treatments for children with catatonia, helping them to recover more quickly and improving their quality of life. If this study shows that the advanced testing approach is more effective in finding the underlying causes of catatonia, this could change the way doctors approach the diagnosis and treatment of this complex condition. In turn, this could lead to more accurate diagnoses, tailored treatments, and improved outcomes for children with catatonia and their families.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individual in whom one of the following criteria is met:
  • Child/adolescent Ages 0-17 (2) with a diagnosis of catatonia.

OR

  • Biological parents of child/adolescent enrolled in this study for the purposes of reflex testing. Family members are eligible for participation in this study if they are presumed to be genetically related to a patient participant

Exclusion criteria

  • Child/adolescents patients who do not meet any of the inclusion criteria, or those who:
  • Already received any prior whole genome sequencing or exome sequencing.
  • Unable to approach the family or patient for enrollment.
  • Unable to obtain informed consent.
  • Family members are ineligible for participation in this study if:
  • They are known to not be genetically related to the child/adolescent patient participant

Treatment and study plan

Genetic: Genomic sequencing and molecular diagnostic results, if any.

Genetic

Genomic sequencing results may be used for diagnosis and treatment of participants.

Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)

Diagnostic Test

Whole Proteome programmable phage display immunoprecipitation sequencing will be used to diagnose known and novel autoantibodies.

Primary outcomes

  1. Diagnostic rate of whole genome sequencing

    Time frame: 2 years

    Evaluate the impact of whole genome sequencing on diagnostic yield in pediatric catatonia, compared to standard medical workup.

  2. Diagnostic rate of brain reactive autoantibodies

    Time frame: 2 years

    Diagnostic rate of brain reactive autoantibodies via genomic and whole human proteome programmable phage display immunoprecipitation sequencing (PhIP-Seq)

Study contacts

Contact information is provided by the study sponsor or research team.

Aaron Besterman, MD

CONTACT

[email protected]

858-576-1700 ext. 221633

Corrine Blucher, BS

CONTACT

[email protected]

858-576-1700 ext. 221632

Sponsors and collaborators

Lead sponsor

Rady Pediatric Genomics & Systems Medicine Institute

Other

Collaborators

  • Brain & Behavior Research Foundation

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2030
First posted
Oct 24, 2024
Registry last updated
Nov 14, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.